Allakos Stock Price - ALLK

-0.51 (-1.14%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Allakos Inc ALLK NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.51 -1.14% 44.26 43.23 46.38 44.37 44.77 14:58:31
Bid Price Ask Price Spread Spread % News
44.10 44.31 0.21 0.47% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
3,406 236,438 $ 44.48 $ 10,515,808 473,460 30.32 - 139.99
Last Trade Time Type Quantity Stock Price Currency
14:58:30 11 $ 44.10 USD

Allakos Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 2.16B 48.71M $ -43.54M -1.89 - 48.39M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Allakos News

Loading Messages....

Latest ALLK Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ALLK Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week58.2062.2443.2350.58572,078-13.94-23.95%
1 Month65.2666.9941.60554.29450,489-21.00-32.18%
3 Months92.2193.5341.60565.56419,625-47.95-52.0%
6 Months78.88139.9941.60582.93419,377-34.62-43.89%
1 Year40.97139.9930.3272.06443,3843.298.03%
3 Years27.20139.9926.0062.23384,83117.0662.72%
5 Years27.20139.9926.0062.23384,83117.0662.72%

Allakos Description

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.